Inovio Pharmaceuticals announced VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was selected for the “Best Therapeutic Vaccine” award at the World Vaccine Congress held in Washington, D.C. Each year, the Vaccine Industry Excellence (ViE) award recognizes a therapeutic vaccine that addresses an unmet medical need and holds significant potential for vast geographical and market reach, as judged by a panel of global biotech industry stakeholders.
VGX-3100 has been evaluated for the treatment of HPV 16 and HPV 18 infection and pre-cancerous lesions of the cervix (Phase 3) and vulva and anus (Phase 2). In a randomized, double-blind, placebo-controlled Phase 2b study in 167 adult women with histologically documented HPV 16/18 cervical HSIL (CIN2/3), treatment with VGX-3100 resulted in a statistically significantly greater decrease in cervical HSIL and clearance of HPV infection vs. placebo. The most common side effect was injection site pain, and no serious adverse events were reported. A phase 3 trial, REVEAL 1, is underway.
VGX-3100 is a DNA-based immunotherapy developed for HPV infection of the cervix and as the first non-surgical treatment for precancerous cervical lesions. VGX-3100 works by stimulating a specific immune response to HPV-16 and HPV-18, which targets the infection and causes destruction of precancerous cells. VGX-3100 utilizes the patient’s own immune system to clear HPV 16 and HPV 18 infection and precancerous lesions without the increased risks associated with surgery, such as loss of reproductive health and negative psychosocial impacts.